With only weeks to go, are we ready for Brexit?

brexit_big

With a matter of weeks to go until the UK is due to leave the European Union, negotiations between warring factions in the British political establishment threaten to derail any prospect of a staged, sensibly managed exit process.

While UK Prime Minister Theresa May has presented a plan, agreed with the EU, for a 20 month “transition period” - under which many of the rules of trade would remain the same, allowing time for further discussion on a permanent settlement - that deal remains in limbo, after being roundly rejected by the British Parliament last month.

As things stand, if the government cannot get the withdrawal agreement through Parliament - and many in Mrs May’s own party reject it outright - the UK will crash out of the 28-nation trading bloc on March 29, uprooting all the settled rules of trade, including customs arrangements and regulatory agreements.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical